Anzeige
❌
Mehr »
Donnerstag, 19.11.2026 - Börsentäglich über 12.000 News
Folge dem Geld: Methan im Fokus der COP31!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
FI

WKN: A426UV | ISIN: US31573L2043 | Ticker:
NASDAQ
18.11.26 | 22:00
0,840 US-Dollar
-6,72 % -0,061
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
FIBROBIOLOGICS INC Chart 1 Jahr
5-Tage-Chart
FIBROBIOLOGICS INC 5-Tage-Chart

Aktuelle News zur FIBROBIOLOGICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
MoFibroBiologics reports Q3 results1
12.11.RedChip Companies, Inc.: Join FibroBiologics' Live Investor Webinar: Advancing a Fibroblast-Based Cell Therapy Platform Across Multiple High-Value Indications248Learn how FibroBiologics is developing an off-the-shelf therapeutic platform designed to harness the regenerative and immune-modulating properties of fibroblastsManagement to discuss the ongoing Phase...
► Artikel lesen
FIBROBIOLOGICS Aktie jetzt für 0€ handeln
19.10.FibroBiologics presents data on disc disease treatment approach1
14.10.FibroBiologics receives Australian patent acceptance for disc treatment2
14.10.FibroBiologics, Inc.: FibroBiologics Announces Australian Patent Accepted for Cellular Blend for the Regeneration of Chondrocytes and Cartilage Cells in Degenerated Spinal Discs306Accepted Patent Contains Claims Covering Methods of Combining Fibroblasts, Platelet Rich Plasma, and Nucleus Pulposus Conditioned Media to Regenerate Cartilage and...
► Artikel lesen
08.10.FibroBiologics, Inc. - 8-K, Current Report2
07.10.FibroBiologics, Inc.: FibroBiologics Files Patent Application for Technology Designed to Produce GLP-1 and Other Therapeutic Peptides Inside the Body237New approach proposes an alternative to repeated injections HOUSTON, Oct. 7, 2026 /PRNewswire/ -- FibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics"), a clinical-stage...
► Artikel lesen
07.10.EXCLUSIVE: FibroBiologics Files Patent Application For Cell-Based Alternative to GLP-1 Injections1
02.10.XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 02.10.2026 -4-2.876The following instruments on Boerse Frankfurt do have their last trading day on 02.10.2026Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 02.10.2026ISIN NameUS1509643029 CENNTRO...
► Artikel lesen
29.09.FibroBiologics erhält europäisches Patent für Fibroblasten-Therapie4
25.09.RedChip Companies, Inc.: Nova Minerals and FibroBiologics Interviews to Air Nationally on the RedChip Small Stocks, Big Money Show on CNBC and Bloomberg TV639ORLANDO, FL / ACCESS Newswire / September 25, 2026 / RedChip Companies will air interviews with Nova Minerals Corp (NYSE American:NVA)(ASX:NVA) and FibroBiologics, Inc. (NASDAQ:FBLG) on the RedChip...
► Artikel lesen
17.09.FibroBiologics CSO invests $500,000 in private placement1
15.09.FibroBiologics, Inc. - 8-K, Current Report2
08.09.RedChip Companies, Inc.: Join FibroBiologics' Live Investor Webinar: Advancing a Fibroblast-Based Cell Therapy Platform Across Multiple High-Value Indications301Learn how FibroBiologics is developing an off-the-shelf therapeutic platform designed to harness the regenerative and immune-modulating properties of fibroblastsManagement to discuss the ongoing Phase...
► Artikel lesen
26.08.FibroBiologics, Inc.: FibroBiologics Regains Compliance with Nasdaq Trading Rules225HOUSTON, Aug. 26, 2026 /PRNewswire/ -- FibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics" or the "Company"), a clinical-stage biotechnology company with 270+...
► Artikel lesen
24.08.FibroBiologics, Inc. - 8-K, Current Report3
24.08.FibroBiologics appoints Leigh Steinberg to board3
20.08.FibroBiologics receives Australian patent for disc disease therapy1
18.08.FibroBiologics Says Preclinical Data Shapes Design of Further Studies for Degenerative Joint Treatment1
18.08.FibroBiologics meldet erfolgreiche Knorpelreparatur in Tierstudie3
1 2 3 Weiter >>
54 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1